Ovid Therapeutics (OVID) Competitors

Senti Biosciences (NASDAQ:SNTI) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Do analysts rate SNTI or OVID?

Senti Biosciences presently has a consensus price target of $12.00, indicating a potential upside of 277.36%. Ovid Therapeutics has a consensus price target of $3.03, indicating a potential upside of 921.32%. Given Ovid Therapeutics' higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is SNTI or OVID more profitable?

Senti Biosciences has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%

Does the MarketBeat Community believe in SNTI or OVID?

Ovid Therapeutics received 353 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 71.03% of users gave Ovid Therapeutics an outperform vote while only 45.45% of users gave Senti Biosciences an outperform vote.

Company	Underperform	Outperform
Senti Biosciences	Outperform Votes 5 45.45%	Underperform Votes 6 54.55%
Ovid Therapeutics	Outperform Votes 358 71.03%	Underperform Votes 146 28.97%

Do insiders & institutionals believe in SNTI or OVID?

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has better earnings and valuation, SNTI or OVID?

Ovid Therapeutics has lower revenue, but higher earnings than Senti Biosciences. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56M	32.40	-$71.06M	-$10.84	-0.29
Ovid Therapeutics	$548K	38.54	-$52.34M	-$0.35	-0.85

Does the media favor SNTI or OVID?

In the previous week, Ovid Therapeutics had 12 more articles in the media than Senti Biosciences. MarketBeat recorded 16 mentions for Ovid Therapeutics and 4 mentions for Senti Biosciences. Ovid Therapeutics' average media sentiment score of 0.53 beat Senti Biosciences' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, SNTI or OVID?

Senti Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats Senti Biosciences on 14 of the 18 factors compared between the two stocks.